Navigation Links
MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
Date:2/1/2011

MARIETTA, Ga., Feb. 1, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that they will be attending the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, February 15 – 19, 2011.  The meeting will be held at the San Diego Convention Center in San Diego, California.  

MiMedx reported that it will have a sizable presence at AAOS this year to present the potential  numerous trauma, sports medicine, spine and wound care applications that are being developed with the Company's three technologies, CollaFix™, HydroFix™ and its newest technology, AmnioFix™.   During the week of the conference, MiMedx plans to hold various meetings with physicians and scientists to demonstrate the benefits of its current and potential products and implants and share the progress being made in its CollaFix™ technology.

MiMedx recently acquired its AmnioFix™ technology through the acquisition of Surgical Biologics, the leading processor of amniotic tissue and the developer of the patent-pending Purion® process.

MiMedx Group will be located in Booth 5915 at the San Diego Conference Center.  

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures. MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. Stunning Attendance for ChemOutsourcing Show on September 8-9 in Long Branch, NJ
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
8. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
9. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
10. Early-Bird Pricing Ends Soon for MichBio Expo Attendees and Exhibitors; Award Nominations Due Nov. 1
11. National Ergonomics Expo Sees 86% On-Site Exhibitor Renewal Rate for 2009; New Products from Contour Design, Equipois, Goldtouch and Herman Miller Win 2008 NECE Attendees Choice New Product Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... San Diego, CA (PRWEB) , ... May 20, ... ... decision support tool that helps avoid the lengthy trial and error process by ... for patients. It can also strengthen the doctor-patient relationship through a personalized ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... 28, 2017 at the Prince Of Wales Private Hospital. The procedure was performed ... C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The AxioMed ...
(Date:5/18/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... May 17, 2017 , ... ... senior business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical ... In addition to his position at Eurofins and Cardinal Health, he was former Chief ...
(Date:5/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... May 17, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the Chairman of the UDIs and Traceability for Medical Devices conference in Brussels, ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):